Introduction
Converging evidence has implicated synaptic dysfunction and degeneration as key components in the neuropathology of schizophrenia [1] . Synapses exhibit extensive morphological plasticity after receptor activation, and morphological change is facilitated by the dynamic actin cytoskeleton [2] . Altered morphology of dendritic spines has been documented in multiple brain regions and is one of the most well-characterized neurobiological changes in schizophrenia [3] . Our laboratory has previously reported abnormal expression of cytoskeletal regulators in schizophrenia brains, including decreased protein levels of duo, cell division cycle protein 42, and myristoylated alanine-rich C kinase substrate (MARCKS), as well as decreased phosphorylation of p21-activated kinase 1 and MARCKS [4, 5] .
The actin-related protein-2/3 (Arp2/3) complex is a chief initiator of actin polymerization and governs the formation of branched actin networks [6] . Conditional knockout of the Arp2/3 complex has been shown to lead to loss of spine synapses, consistent with dendritic spine abnormalities reported in schizophrenia [3, 7] . The Arp2/3 complex consists of seven subunits: Arp2, Arp3, and five other subunits [6] . The Arp2/3 complex is regulated by members of the Wiskott-Aldrich syndrome protein (WASP) family of proteins, comprising the WASP/neuronal-WASP (N-WASP) class of proteins and the SCAR/ WASP-family verprolin homology protein (SCAR/ WAVE) class of proteins [6] . Specifically, binding of WASP-family proteins or cortactin, a key branched actin regulator and Src kinase substrate, activates the Arp2/3 complex [8, 9] . Interestingly, it has been shown in hippocampal neurons that, similar to knockout of the Arp2/3 complex, small interfering RNA knockdown of cortactin results in decreased dendritic spine density [10] . Abelson interactor 1 (Abi1) is an adaptor protein that binds WAVE1 and is critical for neurotypical dendritic spine morphology through interaction with Ca 2 + /calmodulindependent kinase IIα [11, 12] .
Abnormal cytoskeletal dynamics, including disrupted actin polymerization and reorganization, have been implicated in the pathophysiology of schizophrenia. Disruption of signaling cascades converging upon the Arp2/3 complex, necessary for cytoskeletal regulation, may represent a possible mechanism underlying abnormal dendritic spine morphology in schizophrenia. In this study, we hypothesized that the Arp2/3 complex and/or its activators and associated proteins may be abnormally expressed in schizophrenia. To test our hypothesis, we carried out western blot analysis to measure the protein expression of Arp2, Arp3, WAVE1, N-WASP, isoforms of cortactin, and Abi1 in post-mortem superior temporal gyrus (STG) specimens from schizophrenia and paired comparison participants.
Methods

Participants, tissue acquisition, and sample preparation
Samples of gray matter comprising the full cortical thickness of the left STG (Brodmann area 22) were obtained from the Mount Sinai Medical Center brain collection. The STG was studied as a decreased volume of this cortical region has been found in schizophrenia, and the left STG has been linked to auditory hallucinations, disrupted thought processes, and impaired working memory in schizophrenia [13] [14] [15] . Schizophrenia patients (N = 13: age = 77 11 years; tissue pH = 6.5 0.2; postmortem interval = 11.1 6.6 h; six men, seven women) and comparison participants (N = 13; age = 81 7 years; tissue pH = 6.5 0.3; post-mortem interval = 12.8 8.3 h; six men, seven women) were paired by age, sex, tissue pH, and post-mortem interval. The diagnosis of schizophrenia was determined by two independent clinicians on the basis of Diagnostic and Statistical Manual of Mental Disorders, 3rd revision criteria. All patients had a history of psychotic symptoms before the age of 40 years and had at least 10 years of hospitalization. Patients were recruited prospectively and underwent extensive antemortem clinical assessment. Patient medical history was assessed for alcoholism, substance abuse, death by suicide, coma for more than 6 h before death, or evidence of neurodegenerative disorders, and they were excluded if any of these were present. Comparison participants were assessed similarly and confirmed to be without neuropathological evidence of neurodegenerative disorders and a history of psychiatric illness or substance abuse.
Brains were collected at autopsy, as previously described [16] . Briefly, each sample was snap frozen, pulverized into a powder with small amounts of liquid nitrogen, and stored at − 80°C until use. The samples were subsequently reconstituted and homogenized in cold RIPA buffer [50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.5 mM EGTA, 1 mM EDTA, 1% Tritonx-100, 1% sodium deoxycholate, 0.5% SDS, deubiquitinase inhibitors, and a protease and phosphatase inhibitor tablet (Complete Mini and Phostop, respectively; Roche Diagnostics, Manheim, Germany)] using a Power Gen 125 homogenizer (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Homogenates were assayed for protein concentration using a BCA protein assay kit (Thermo Fisher Scientific) and stored at − 80°C until use.
Antipsychotic-treated rats
Animal studies and procedures were approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham. Efforts were made to minimize the number of animals used and any unnecessary suffering. Twenty house-paired male Sprague-Dawley rats (250 g; Charles River, Wilmington, Massachusetts, USA) were intramuscularly injected every 3 weeks with either haloperidol decanoate in sesame oil (28.5 mg/kg, 10 rats) or sesame oil only (10 rats) for a total of 12 injections. Haloperidol decanoate is a firstgeneration, long-acting antipsychotic that is administered monthly to patients. The goal of this rat study was to emulate chronic antipsychotic treatment used in patients. The dose and duration of treatment were converted from patient-appropriate doses to rat-appropriate doses to recapitulate chronic treatment with typical antipsychotics, and have been previously described [4, 5] . The animals were killed by decapitation, and their brains were immediately harvested, dissected, and stored at − 80°C.
Western blot analysis
Each sample was diluted to a concentration of 1 μg/μl and denatured at 70°C for 10 min under reducing conditions. For each participant, 10 μg total protein per lane was loaded in duplicate into 4-12% gradient bis-tris polyacrylamide gels (Life Technologies, Grand Island, New York, USA) and electrophoresed using the Novex Mini Cell NuPAGE system (Life Technologies).
After electrophoresis, the proteins were transferred onto nitrocellulose membranes (Bio-Rad, Hercules, California, USA) using a semi-dry transfer apparatus (Bio-Rad). The membranes were blocked with either Odyssey blocking buffer (LI-COR Biosciences, Lincoln, Nebraska, USA) or 5% BSA in PBS for 1 h at room temperature before incubation with primary antibodies (conditions listed in Table 1 ). The membranes were washed with PBS containing 0.1% Tween-20 and then probed with IR-dyelabeled secondary antibodies (LI-COR Biosciences). A final wash with PBS containing 0.1% Tween-20 was performed before scanning the membranes using an Odyssey Infrared Imaging System (LI-COR Biosciences) at an intensity of 5.0 and resolution of 169 μm. Vasolincontaining protein (VCP; 110 kDa) was chosen as a loading control because it is ubiquitously expressed in the human brain, and VCP was verified to be unchanged in schizophrenia, consistent with prior reports [17] . 
Results
Cortactin expression is decreased in schizophrenia
We measured the protein expression of Arp2, Arp3, N-WASP, WAVE1, Abi1, and cortactin in the STG of paired schizophrenia and comparison participants. The antibody used for cortactin recognized three unique isoforms, consistent with previous reports [18, 19] . We found decreased expression of all three isoforms of cortactin ( Fig. 1) in patients with schizophrenia, whereas none of the other proteins showed different expression between groups (Arp2, t = 0.84; Arp3, t = 1.69; N-WASP, t = 0.40; WAVE1, W = − 25; Abi1, W = 45; Fig. 2 , Table 2 ). Cortactin isoform 1 (62 kDa) was decreased by 43%, isoform 2 (71 kDa) was decreased by 32%, and isoform 3 was decreased by 35%. Correlation analysis of all significant dependent measures with age, pH, and postmortem interval revealed no significant correlation between protein expression and any of these variables.
Haloperidol does not alter the expression of cortactin in rat brain
To address the possibility that changes in the expression of the three isoforms of cortactin were because of schizophrenia patients receiving antipsychotic treatment, we conducted parallel experiments in rats chronically treated with haloperidol decanoate. Protein expression of the three cortactin isoforms was not different between haloperidol-treated and vehicle-treated rats (Fig. 1 ).
Discussion
In this study, we assessed the expression of proteins directly involved in Arp2/3 complex-dependent actin polymerization in the STG of schizophrenia and comparison participants. We found decreased expression of all three isoforms of cortactin in schizophrenia, whereas there were no differences in the expression of Arp2, Arp3, WAVE1, N-WASP, or Abi1 between groups. The expression of these cortactin isoforms was unchanged in the cortex of rats chronically treated with haloperidol.
The filamentous actin (F-actin)-binding protein, cortactin, has been implicated in the progression of many cancers [20] , although its role in neuropsychiatric illness is not well-defined. Cortactin plays a role in actin polymerization by binding and activating the Arp2/3 complex at its N-terminal acidic domain [18] , and knockdown of cortactin has been shown to lead to diminished dendritic spine density and formation in vitro, potentially through interaction with Dock4 [10, 21] . Three isoforms of cortactin arising from two splice variants have been identified [18, 19] . Compared with isoforms 1 (62 kDa) and 2 (71 kDa), isoform 3 (58 kDa) exhibits decreased F-actin bundling activity, leading to a reduction in Arp2/3 recruitment to F-actin and Arp2/3 complex-mediated actin polymerization [19] . Cortactin-mediated activation of the Arp2/3 complex differs from WASP or SCAR/ WAVE-mediated activation, in that cortactin-mediated Arp2/3 activation moderately potentiates actin nucleation and leads to assembly of stable branched actin networks, whereas WASP or SCAR/WAVE-mediated activation strongly potentiates actin nucleation but leads to the formation of unstable branched actin networks that quickly disassemble [22] . Our finding of decreased expression of all three isoforms of cortactin suggests decreased binding and subsequent activation of the Arp2/3 complex, which may lead to reduced assembly of stable actin networks in schizophrenia and hence contribute to abnormal dendritic spine morphology.
We did not find altered expression of Arp2 or Arp3, although the function of the Arp2/3 complex may be compromised in schizophrenia. For example, protein-protein interactions within the complex may be altered, diminishing the activity of the complex in nucleating F-actin. Recently, Arp2/3-knockout mice were found to exhibit many hallmark neurobiological traits of schizophrenia, including decreased spine formation, enhanced excitation of cortical neurons, and abnormal striatal output, suggesting dysfunction of the complex in this illness [23] . Phosphorylation of Arp2/3 complex activators may also be dysregulated. WAVE1 phosphorylation has been shown to inhibit Arp2/3 complex-dependent actin polymerization and decrease dendritic spine density [24] , and N-WASP will only bind and activate the Arp2/3 complex upon phosphorylation at the Tyr-526 residue [25] .
There are limitations to this study. The patients studied were elderly and in the late stages of this disorder, and these findings may not be generalizable to younger patients. Potential effects of chronic antipsychotic treatment on dependent measures are a concern in schizophrenia studies. We assessed the expression of the three isoforms of cortactin in the frontal cortex of rats chronically treated with haloperidol and found no difference in these protein levels. Accordingly, it is unlikely that the abnormal protein expression we report here is caused by medication effects, and it is more likely associated with the illness itself.
Conclusion
We found decreased expression of all three isoforms of cortactin in the schizophrenia brain. This alteration may attenuate stable branched actin network formation and thereby contribute to the altered dendritic spine pathology observed in schizophrenia. As dendritic spines are the prime recipients of excitatory synaptic input, a decrease in dendritic spine density can impair synaptic plasticity, which may contribute to the cognitive dysfunction associated with schizophrenia. These data implicate dysregulated cortactin-mediated Arp2/3 complex-dependent actin polymerization as a potential substrate of the pathophysiology of this illness. Representative images of immunoblots illustrating the expression of Arp2, Arp3, N-WASP, WAVE1, and Abi1 in schizophrenia (S) and comparison (C) participants. Expression of these proteins did not differ between participant groups. Abi1, Abelson interactor 1; Arp, actinrelated protein; N-WASP, neuronal-Wiskott-Aldrich syndrome protein; WAVE1, WASP-family verprolin homologous protein 1. Data are averaged target protein expression normalized to intralane vasolincontaining protein (VCP) and are presented as means SD. Abi1, Abelson interactor 1; Arp, actin-related protein; n.s., not significant; N-WASP, neuronal-Wiskott-Aldrich syndrome protein; WAVE1, WASP-family verprolin homologous protein 1.
